Key Highlights

  • Cadrenal stockholders approved an Equity plan increase of 323,542 shares, bringing the total available for awards to 1,000,000 shares.
  • They also approved issuing up to 960,000 shares on exercise of Series C-1 warrants issued on July 1, 2026.
  • Quang X. Pham was re-elected as a Class I director through the 2029 annual meeting.
  • WithumSmith+Brown, P.C. was ratified as independent auditor for the fiscal year ending December 31, 2026, with 2,110,693 votes for.

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) filed a Form 8-K reporting the results of its annual meeting of stockholders, held on September 24, 2026 at 822 A1A North, Suite 306, in Ponte Vedra, Florida. Stockholders re-elected a director, ratified the company's auditor, approved an increase in the shares available under the company's equity incentive plan, and approved the issuance of up to 960,000 shares on exercise of warrants.

The filing, made under Item 5.07, is signed by Quang X. Pham, the company's Chairman and Chief Executive Officer, and is dated September 29, 2026.

Turnout and the Director Vote

The filing states that 2,155,341 shares were present at the meeting, which it describes as 60.4% of the 3,567,592 shares outstanding, establishing a quorum. Quang X. Pham, a Class I director, was re-elected for a term through the 2029 annual meeting, receiving 1,039,666 votes for and 14,342 withheld, with 1,101,333 broker non-votes. WithumSmith+Brown, P.C. was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 2,110,693 votes for, 39,121 against and 5,527 abstentions.

The Equity Plan Increase

Stockholders approved Amendment No. 2 to the Cadrenal Therapeutics, Inc. 2022 Successor Equity Incentive Plan. The amendment increases the shares available for awards by 323,542, bringing the total to 1,000,000 shares. The amendment is filed as Exhibit 10.1. The vote was 694,746 for, 352,409 against and 6,853 abstentions, with 1,101,333 broker non-votes. That was the closest of the substantive proposals: the votes against equalled roughly one-third of the votes cast for and against. Equity plans such as this are used to grant stock Options and other awards to employees, directors and consultants, and share increases typically require stockholder approval so that awards can be granted from the enlarged pool.

The Warrant Share Issuance

The fourth proposal asked stockholders to approve the issuance of up to 960,000 shares of common stock on the exercise of Series C-1 warrants that were issued on July 1, 2026. The filing cites Nasdaq Rule 5635(d) as the basis for the vote. That rule is one of Nasdaq's stockholder-approval requirements, and it generally applies when a listed company issues shares equal to 20% or more of its outstanding common stock in certain transactions. With 3,567,592 shares outstanding, an issuance of 960,000 shares represents roughly 27% of that figure, using the outstanding share count stated in the filing.

The proposal passed with 1,011,206 votes for, 34,449 against and 8,353 abstentions, along with 1,101,333 broker non-votes. Those details would be found in the company's earlier filings from around July 1, 2026.

A fifth proposal, to adjourn the meeting if needed to solicit more votes for the plan amendment or the warrant proposal, was also approved, with 736,364 votes for, 315,865 against and 1,779 abstentions.

Cadrenal's Warrant Exercises and Share Count Ahead

With stockholder approval in hand, the company is authorized to issue up to 960,000 shares if the Series C-1 warrants are exercised. The number of shares actually issued will depend on holders' decisions, and future issuances or changes in the outstanding share count would be reflected in the company's periodic reports and any related current reports. The larger equity plan pool of 1,000,000 shares will be used for awards over time, and the company's next Annual Report and proxy statement should describe grants and compensation. The auditor's work for the fiscal year ending December 31, 2026 will be reflected in the company's annual report for that year.